Ambagon Therapeutics

Ambagon Therapeutics is a biotechnology company focused on developing innovative therapies for challenging protein targets, particularly intrinsically disordered proteins.

Founded in 2020 by Christian Ottmann, Luc Brunsveld, and Michelle Arkin, the company operates from its headquarters in San Carlos, California, and has a significant presence in Eindhoven, Netherlands. With a team of approximately 18 employees, Ambagon has raised over $103 million in funding, including an $85 million Series A round in January 2022. The company’s primary technology is its Molecular Glue Platform, which aims to stabilize protein interactions and modulate protein functions. Ambagon is currently in the discovery phase, working on five programs with a focus on oncology, particularly breast cancer, while also addressing other therapeutic areas such as metabolic disorders and neurodegenerative diseases. The company is expected to announce a development candidate in 2023 and aims to enter clinical trials in 2024.